{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:52:56Z","timestamp":1781844776487,"version":"3.54.5"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acquired lipodystrophy is a rare disorder characterized by adipose tissue loss or dysfunction and is frequently associated with severe insulin resistance and metabolic complications. Metabolic complications of lipodystrophy have occasionally been reported after hematopoietic stem cell transplantation (HSCT), but their clinical features and optimal treatment strategies remain poorly defined. Tirzepatide, a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has recently emerged as a novel therapy for type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a 37-year-old woman who underwent allogeneic HSCT at 12 years of age for relapsed acute lymphoblastic leukemia after a conditioning regimen including total body irradiation (TBI), high-dose cytarabine, and melphalan. She subsequently developed diabetes mellitus and fatty liver disease at 17 years of age. Although no apparent fat loss was initially recognized, lipodystrophy was clinically suspected based on severe insulin resistance and metabolic abnormalities disproportionate to her body habitus. Computed tomography at 37 years of age revealed region-specific fat loss extending from the lower back to the gluteal region. Glycemic control remained inadequate despite high-dose insulin therapy and sequential treatment with several GLP-1 receptor agonists. After initiation of tirzepatide, glycemic control improved dramatically, allowing complete discontinuation of insulin therapy. Body weight decreased modestly and hepatic steatosis improved. The high-molecular-weight (HMW)\/total adiponectin ratio after treatment was elevated (64.0%), suggesting possible improvement in adipocyte secretory function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights acquired partial lipodystrophy developing after HSCT, supported by region-specific fat loss and characteristic metabolic abnormalities, and demonstrates a marked therapeutic response to tirzepatide. Dual incretin receptor agonism may represent a promising therapeutic strategy for severe insulin resistance associated with adipose tissue dysfunction, potentially through both weight-dependent and weight-independent mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1868458","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:28:49Z","timestamp":1781843329000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Dramatic metabolic improvement with tirzepatide in a patient with acquired partial lipodystrophy following hematopoietic stem cell transplantation"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuri","family":"Tanaka","sequence":"first","affiliation":[{"name":"Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki","place":["Kiyotake, Miyazaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ueno","sequence":"additional","affiliation":[{"name":"Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki","place":["Kiyotake, Miyazaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotake","family":"Sawada","sequence":"additional","affiliation":[{"name":"Division of Pediatrics, Faculty of Medicine, University of Miyazaki","place":["Miyazaki, Japan"]},{"name":"Department of Nursing, Faculty of Medicine University of Miyazaki","place":["Miyazaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Konagata","sequence":"additional","affiliation":[{"name":"Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki","place":["Kiyotake, Miyazaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Uchida","sequence":"additional","affiliation":[{"name":"Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki","place":["Kiyotake, Miyazaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Uehira","sequence":"additional","affiliation":[{"name":"Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki","place":["Kiyotake, Miyazaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Kogo","sequence":"additional","affiliation":[{"name":"Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki","place":["Kiyotake, Miyazaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akari","family":"Sekishima","sequence":"additional","affiliation":[{"name":"Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki","place":["Kiyotake, Miyazaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Moritake","sequence":"additional","affiliation":[{"name":"Division of Pediatrics, Faculty of Medicine, University of Miyazaki","place":["Miyazaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki","place":["Kiyotake, Miyazaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki","place":["Kiyotake, Miyazaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4158\/endp.19.1.v767575m65p5mr06","article-title":"The clinical approach to the detection of lipodystrophy - an AACE consensus statement","volume":"19","author":"Handelsman","year":"2013","journal-title":"Endocr Pract"},{"key":"B3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40618-018-0887-z","article-title":"Diagnosis and treatment of lipodystrophy: a step-by-step approach","volume":"42","author":"Ara\u00fajo-Vilar","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/1744666X.2022.2072299","article-title":"Autoimmune diseases after allogeneic stem cell transplantation: a clinician\u2019s guide and future outlook","volume":"18","author":"Faraci","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.71641","article-title":"A case of bone marrow transplant-associated partial lipodystrophy","volume":"16","author":"Khan","year":"2024","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1292\/cpe.22.53","article-title":"Abnormal adipose tissue distribution with unfavorable metabolic profile in five children following hematopoietic stem cell transplantation: a new etiology for acquired partial lipodystrophy","volume":"22","author":"Adachi","year":"2013","journal-title":"Clin Pediatr Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-023-00674-6","article-title":"Influence of diet and body weight in treatment-resistant acquired partial lipodystrophy after hematopoietic stem cell transplantation and its potential for metabolic improvement","volume":"15","author":"Ishida","year":"2024","journal-title":"Diabetol Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s13256-018-1901-y","article-title":"Acquired partial lipoatrophy as graft-versus-host disease and treatment with metreleptin: two case reports","volume":"12","author":"Shibata","year":"2018","journal-title":"J Med Case Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-017-0731-x","article-title":"Acquired partial lipodystrophy after bone marrow transplant during childhood: a novel syndrome to be added to the disease classification list","volume":"40","author":"Ceccarini","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1297\/cpe.26.99","article-title":"Partial lipodystrophy in patients who have undergone hematopoietic stem cell transplantation during childhood: an institutional cross-sectional survey","volume":"26","author":"Adachi","year":"2017","journal-title":"Clin Pediatr Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-1614","article-title":"Efficacy and safety of glucagon-like peptide 1 agonists in a retrospective study of patients with familial partial lipodystrophy","volume":"47","author":"Foss-Freitas","year":"2024","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16175","article-title":"Safety and effectiveness in an uncontrolled setting of glucagon-like-peptide-1 receptor agonists in patients with familial partial lipodystrophy: Real-life experience from a national reference network","volume":"27","author":"Lamothe","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","article-title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor","volume":"36","author":"Regmi","year":"2024","journal-title":"Cell Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1431292","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2413871","article-title":"Tirzepatide for congenital generalized lipodystrophy","volume":"392","author":"Ten","year":"2025","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-2408","article-title":"Metabolic improvements with tirzepatide in lipodystrophy: a novel option","volume":"48","author":"Meral","year":"2025","journal-title":"Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2475090","article-title":"Clinical features of acquired lipodystrophy after total body irradiation: a case report and mini review","volume":"41","author":"Ancona","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081559","article-title":"Lipodystrophy as a late effect after stem cell transplantation","volume":"10","author":"Tews","year":"2021","journal-title":"J Clin Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2018-0356","article-title":"Acquired partial lipodystrophy with metabolic disease in children following hematopoietic stem cell transplantation: a report of two cases and a review of the literature","volume":"32","author":"Hosokawa","year":"2019","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1379228","article-title":"GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy","volume":"15","author":"Roumane","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: Their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2016.03.005","article-title":"Reappraisal of GIP pharmacology for metabolic diseases","volume":"22","author":"Finan","year":"2016","journal-title":"Trends Mol Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1402583","article-title":"Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence","volume":"15","author":"Corrao","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14110","article-title":"The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists","volume":"22","author":"Urva","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2009.171","article-title":"Weight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents","volume":"17","author":"Vitola","year":"2009","journal-title":"Obes (Silver Spring)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/nu13041180","article-title":"Adiponectin: structure, physiological functions, role in diseases, and effects of nutrition","volume":"13","author":"Khoramipour","year":"2021","journal-title":"Nutrients"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-5-200809020-00005","article-title":"Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women","volume":"149","author":"Heidemann","year":"2008","journal-title":"Ann Intern Med"},{"key":"B31","first-page":"298","article-title":"Changes in concentration of serum adiponectin multimeric forms following weight reduction programme in prepubertal obese children","volume":"15","author":"Gajewska","year":"2011","journal-title":"Med Wieku Rozwoj"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2007.02204.x","article-title":"Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes","volume":"24","author":"Aso","year":"2007","journal-title":"Diabetes Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-1306","article-title":"Relationship between metabolic and histological responses in people with metabolic dysfunction- associated steatohepatitis with and without type 2 diabetes: participant-level exploratory analysis of the SYNERGY-NASH trial with tirzepatide","volume":"48","author":"Caussy","year":"2025","journal-title":"Diabetes Care"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14855","article-title":"Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: A meta-analysis of randomized controlled trials","volume":"87","author":"Simental-Mend\u00eda","year":"2021","journal-title":"Br J Clin Pharmacol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1868458\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:28:53Z","timestamp":1781843333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1868458\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":35,"alternative-id":["10.3389\/fendo.2026.1868458"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1868458","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"article-number":"1868458"}}